Anthropic paid $400 million for 8-month-old Coefficient Bio

Anthropic, biotechnology startup Coefficient Bio for about $400 million signed a share agreement worth Two different sources confirmed this acquisition, but the company did not share details about the financial side of the deal. However, the timing of the news is also important, because Anthropic has been health, life sciences And drug discovery He accelerated his moves on his side. Thus, the company took an expansion step beyond general-purpose AI tools.

What stands out about Coefficient Bio is that the company is more eight months ago being established. Samuel Stanton and Nathan C. Frey launched the initiative following their work at Genentech’s Prescient Design unit. The duo will focus on biological research and research in their new company. new drug discovery focused on artificial intelligence to speed up its processes. On the other hand, with the announcement of the acquisition, the name Coefficient Bio reached a wider audience in technology and biotechnology circles.

According to the information in the news, Coefficient Bio’s team is approximately out of 10 is formed. In addition, this team will be working with Anthropic in the coming weeks. health and life sciences He is expected to join the team. This seemingly small staff has a greater meaning due to the background of the founders and the company’s field of work. At first glance it looks like a young startup, but behind the scenes there is a field of expertise focused directly on research efficiency.

The recent steps taken by Anthropic make this acquisition no longer news on its own. Company, October 2025announced Claude for Life Sciences at and integrated with tools like Benchling, PubMed, 10x Genomics, and Synapse.org. Behind last january Claude for Healthcare shared its announcement and introduced new tools for clinical workflows and regulatory processes. Thus, the Coefficient Bio move sat side by side with the product and partnership news that has come in the last few months.

Anthropic accelerated its moves on the health side

Anthropic’s announcements in October and January showed that the company began to group science-oriented usage areas under a separate heading. In addition, the partnership established with Benchling brought together the software flows on the laboratory and research side with Claude. The 10x Genomics collaboration has also opened up a more direct field of use for researchers on the single cell and spatial analysis side. Continuing in this line, the company is now adding the Coefficient Bio team to its structure.

News of the acquisition made the relationship between artificial intelligence companies and the biotechnology world more visible. Google-backed Isomorphic Labs conducts its first clinical trials while continuing its artificial intelligence-based drug development studies. by the end of 2026 postponed. In addition, the collaboration between OpenAI and Moderna has brought generative artificial intelligence to drug development and corporate processes. So major artificial intelligence companies, following the software biology And drug research He turned more strongly to his side.

The Coefficient Bio acquisition aligns Anthropic’s healthcare product announcements with research team expansion. discussed for purchase $400 million The amount was a high level for an eight-month venture. However, the Genentech background of the company’s founders revealed that the acquisition was not only name or technology focused. All indications in the news are that Anthropic Coefficient Bio shows that he brings his team directly to his own health and life sciences work.